Coronavirus Disease 2019 (COVID-19) Clinical Trial
Official title:
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04516564 -
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT04519424 -
CSL324 in COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT04395170 -
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.
|
Phase 2/Phase 3 | |
Completed |
NCT05437289 -
A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults
|
Phase 1 | |
Completed |
NCT05594147 -
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
|
||
Withdrawn |
NCT04848467 -
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
|
Phase 3 | |
Completed |
NCT04588363 -
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
|
||
Terminated |
NCT04877743 -
Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
|
||
Completed |
NCT04742725 -
A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
|
Phase 2 | |
Completed |
NCT04375761 -
COVID-19: Human Epidemiology and Response to SARS-CoV-2
|
||
Completed |
NCT04545047 -
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
|
||
Completed |
NCT04378777 -
Immunophenotyping Assessment in a COVID-19 Cohort
|
||
Completed |
NCT04327206 -
BCG Vaccination to Protect Healthcare Workers Against COVID-19
|
Phase 3 | |
Terminated |
NCT05375760 -
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
|
Phase 2 | |
Completed |
NCT04344977 -
Collection of Anti-SARS-CoV-2 Immune Plasma
|
||
Terminated |
NCT04389840 -
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04425733 -
MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)
|
Phase 1 | |
Not yet recruiting |
NCT04438837 -
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers
|
N/A | |
Completed |
NCT04275245 -
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia
|
Phase 1/Phase 2 | |
Terminated |
NCT04638634 -
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
|
Phase 1 |